| aspirin versus placebo | |||
| EAFT, 1993 | aspirin 300 mg/d versus placebo | Patient with non rheumatic AF and recent TIA or minor ischaemic stroke(secondary prevention). | Double blind Follow-up duration: 2.3 years europe,israel |
| aspirin versus placebo (on top fluidione) | |||
| FFAACS , 2001 | fluidione standard dose (target INR: 2-2.6) + aspirin low dose 100 mg versus fluidione standard dose(target INR:2-2.6) + placebo | high risk patients with non valvular atrial fibrillation | Double blind Follow-up duration: 0.84 y France |
| dabigatran 100mg versus warfarin | |||
| RE-LY 110mg (2nd prevention subgroup) , 2010 | dabigatran 110mg daily
versus warfarin | patients with a prior stroke or transient ischemic attack | open Follow-up duration: 2 y |
| dabigatran 150mg versus warfarin | |||
| RE-LY 150mg (2nd prevention subgroup) , | dabigatran 150mg daily versus warfarin | patients with a prior stroke or transient ischemic attack | open Follow-up duration: 2 y |
| Indobufen versus warfarin | |||
| SIFA, 1997 NCT00244426 | indobufen 200 mg (the dose was lowered to 100 mg if impaired renal function:cc<80 ml/mn) versus warfarin standard dose(target INR 2.0-3.5) | non rhumatismal AF and recent cerebral ischemic episode(< or =15 days) | Open Follow-up duration: 12 months Italy |
| oral anticoagulant versus placebo | |||
| EAFT, 1993 | Oral anticoagulation standard dose(target INR 3.0 (2.5-4.0)) the choice of anticoagulant type was free but most physicians choose coumarin derivatives. versus placebo | Patient with non rheumatic AF and recent TIA or minor ischaemic stroke(secondary prevention). | Open Follow-up duration: 2.3 years |
| rivaroxaban versus warfarin | |||
| ROCKET (2nd prevention subgroup) , 2011 | rivaroxaban versus warfarin INR 2-3 | patients with a prior stroke or transient ischemic attack | double-blind |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
